Bumetanide in Heart Failure Management
Primary Indications and Clinical Applications
- The American College of Cardiology recommends bumetanide as a loop diuretic for reducing fluid retention in heart failure patients by inhibiting sodium and chloride reabsorption at the loop of Henle, providing rapid and effective diuresis 1, 2
- Bumetanide is effective for managing edema and ascites associated with liver cirrhosis, as supported by the guidelines from Gut 3
- The American College of Cardiology suggests using bumetanide as part of standard heart failure therapy alongside ACE inhibitors/ARBs and beta-blockers for patients with fluid retention, with an initial daily dose typically 0.5-1.0 mg once or twice daily, and a maximum total daily dose of 10 mg 1, 2, 4
- The treatment goal with bumetanide is to eliminate clinical evidence of fluid retention using the lowest effective dose to maintain euvolemia, as recommended by the American College of Cardiology 4
- Bumetanide reduces jugular venous pressures, pulmonary congestion, peripheral edema, and body weight within days of initiation in heart failure patients, according to the American College of Cardiology 1
- The American College of Cardiology notes that bumetanide may be more effective than oral furosemide in patients with gut wall edema due to better absorption 5